DOCSLIB.ORG

View Annual Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
View Annual Report Annual Report 2009 FROM DISTRIBUTION TO GLOBAL HEALTHCARE United Drug plc Annual Report 2009 About Us United Drug is a leading international healthcare services provider, employing over 3,800 people in 32 businesses across Europe and the US. United Drug operates through three divisions... HEALTHCARE PACKAGING & CONTRACT SALES & SUPPLY CHAIN SPECIALITY MARKETING SERVICES BLACKHALL ENESTIA ALLIANCE HEALTHCARE CRAIG & HAYWARD EUROPEAN PACKAGING CENTRE ASHFIELD IN2FOCUS ENDOSCOPY UK MASTA ASHFIELD IRELAND INTRA PHARMA MEDCO HEALTH SOLUTIONS ASHFIELD USA INTRA VENO SHARP BEST JVA ANALYTICAL TEMPERATURE CONTROLLED PHARMACEUTICALS UNIVERSALPROCON MANTIS SURGICAL TD PACKAGING NEW SPLINT PEMBERTON PRESEARCH PYRAMED SANGERS THE SPECIALS LABORATORY UNIDRUG DISTRIBUTION GROUP (UDG) UNITECH UNITED DRUG DISTRIBUTORS UNITED DRUG WHOLESALE ULSTER ANAESTHETICS VEROTECH Our Purpose Excellent manufacturer solutions, better patient care. Ambition Our ambition is to be a dynamic, leading international healthcare services company, fostering enhanced patient outcomes through partnerships with healthcare manufacturers, government agencies, providers and payors. HIGHLIGHTS CONTENTS Revenue Operating Highlights and Overview 1 Financial Highlights profit 2 Business Overview OVERVIEW €1,717.9m €76.8m AND HIGHLIGHTS constant currency increase 5% constant currency increase 5% Profit Dividend before tax per share Business Review 4 Chairman’s Statement €66.9m 8.00 cent 6 Chief Executive’s Review constant currency increase 2% 2008: 8.00 cent 8 Operations Review 20 Finance Review 24 Corporate Social Responsibility REVIEW BUSINESS Amortisation of intangible Constant assets and Increase/ currency * IFRS exceptional (decrease) increase/ based item Adjusted on 2008 (decrease) €’mn €’mn €’mn % % Revenue 1,717.9 - 1,717.9 2 5 Operating profit 49.0 27.8 76.8 (2) 5 Profit before tax 39.1 27.8 66.9 (5) 2 Diluted earnings per share (cent) 14.22 9.20 23.42 (9) (2) 2009 2008 Governance Dividend per share (cent) 8.00 8.00 26 Board of Directors Net debt 162.5 159.1 28 Directors’ Report 32 Directors’ Statement on Corporate Net debt/EBITDA** (times) 1.78 1.65 GOVERNANCE Governance 39 Report of the Remuneration Committee on * all constant currency figures are based on retranslating current year figures at prior year exchange rates Directors’ Remuneration ** EBITDA before exceptional item including annualised EBITDA of companies acquired during the year 46 Statement of Directors’ Responsibilities United Drug believes that the adjusted operating profit, adjusted profit before tax and adjusted diluted earnings per share are more appropriate measures of the underlying group performance than those measurements set out in the primary financial statements, as this information is in a format communicated to and reviewed by the investment community. Financial Statements COMPOUND AVERAGE 47 Independent Auditor’s Report 49 Group Income Statement ANNUAL GROWTH RATES 50 Group Statement of Recognised Income and Expense 51 Group Balance Sheet 52 Group Cash Flow Statement 53 Significant Accounting Policies STATEMENTS FINANCIAL 62 Notes forming part of the Group % % % % Financial Statements 5 year 10 year 15 year 20 year 101 Company Statement of Recognised Revenue 7 11 15 18 Income and Expense Profit before tax 10 17 18 18 102 Company Balance Sheet 103 Company Cash Flow Statement Diluted earnings per share 8 14 14 12 104 Notes forming part of the Company Dividend per share 11 13 13 12 Financial Statements 116 Shareholder and Other Information 1 United Drug plc Annual Report 2009 BUSINESS OVERVIEW DIVISION HEALTHCARE SUPPLY CHAIN DESCRIPTION The Healthcare Supply Chain division combines all of the Group’s healthcare logistics based businesses. Overall revenues for the division in the year of €1.45 billion are 2% lower than revenues in 2008. On a constant currency basis, revenues are 1% higher than 2008. LOCATIONS STRUCTURE United Drug Wholesale Unitech/Intra Veno/Intra Pharma Provides time-critical Provide contract distribution pharmaceutical delivery services, services, sales and marketing together with complementary and technical support to medical pharmacy products to retail and and scientific equipment and hospital pharmacies, throughout the consumable manufacturers in the Republic of Ireland. Republic of Ireland. Sangers Mantis Surgical/New Splint/Ulster Provides time-critical Anaesthetics pharmaceutical delivery services, Provide contract distribution together with complementary services, sales and marketing and pharmacy products to retail and technical support to medical and hospital pharmacies, throughout scientific equipment and consumable Northern Ireland. manufacturers in the UK. Craig & Hayward Presearch Provides time-critical delivery Provides contract distribution services of specially prepared services, sales and marketing and products manufactured to meet technical support to laboratory specific patients’ prescription instrumentation and consumable requirements. manufacturers in the UK. The Specials Laboratory Endoscopy UK Manufactures unlicensed medicines Provides medical distribution for the retail pharmaceutical and services, specialising in the sales hospital markets. and technical support of flexible endoscopy equipment. United Drug Distributors Provides contract distribution and Pyramed other services to pharmaceutical and Provides medical distribution animal health manufacturers in the services, specialising in surgical Republic of Ireland. products in the cardiology, radiology, neuroradiology and cardiothoracic UniDrug Distribution Group (UDG) sectors. Provides contract distribution and other services to pharmaceutical JVA Analytical and animal health manufacturers Provides contract distribution, sales in the UK. and marketing and technical support services to Ireland’s analytical, Pemberton/Blackhall environmental, educational and regulatory laboratories. Provide sales, marketing and contract distribution services to consumer products and health Verotech and beauty manufacturers in the Provides contract distribution, sales Republic of Ireland. and marketing and technical support services to Sweden’s analytical, environmental, educational and regulatory laboratories. 2 PACKAGING & CONTRACT SALES & SPECIALITY MARKETING SERVICES OVERVIEW In the Packaging & Speciality division, United The Contract Sales & Marketing Services division Drug provides outsourced packaging solutions for provides contract sales outsourcing and related pharmaceutical manufacturers through facilities marketing services to healthcare manufacturers AND HIGHLIGHTS in the US, the UK, The Netherlands and Belgium. in the UK, Ireland and the US. Revenues for the Overall revenues for the division of €118 million year of €153 million are 13% higher than revenues are 66% higher than revenues in 2008 including a in 2008. Revenue growth is 26% on a constant full year contribution from Sharp. currency basis. TD Packaging MASTA Ashfield In2Focus Alliance Healthcare Provides primary and secondary Healthcare service provider in the Provides contract sales outsourcing Provides sales and marketing packaging solutions to the travel field, specialising in the sale and sales and marketing services services to pharmaceutical healthcare industry specialising and distribution of vaccines, medical to pharmaceutical manufacturers manufacturers in the US. in nutraceutical and generic information and provision of clinical in the UK. production. services. UniversalProcon Ashfield Ireland Provides event management Enestia Medco Health Solutions Provides contract sales outsourcing services to the pharmaceutical Provides customised packaging Provides specialty and homecare and sales and marketing services to sector. solutions to the healthcare industry. services to the NHS and the UK pharmaceutical manufacturers in pharmaceutical industry. the Republic of Ireland. BEST European Packaging Centre (EPC) Provides sales force effectiveness Temperature Controlled Ashfield USA training services to the Provides primary and secondary Pharmaceuticals packaging solutions to the generic Provides contract sales outsourcing pharmaceutical sector. Provides nurse-led homecare and sales and marketing services pharmaceutical industry. services to the Irish healthcare to pharmaceutical manufacturers sector. in the US. Sharp Provides primary and secondary packaging solutions to the healthcare industry. 3 United Drug plc Annual Report 2009 CHAIRMAN’S STATEMENT Financial Performance market and the systems that have been developed by them will be important to AGAINST A VERY DIFFICULT ECONOMIC the successful development of this new BACKGROUND, PRE-TAX PROFITS BEFORE business. AMORTISATION OF INTANGIBLE ASSETS AND THE EXCEPTIONAL ITEM WERE 2% AHEAD OF LAST People The skills, experience and dedication of YEAR, ON A CONSTANT CURRENCY BASIS. THIS our people are critical to the success of PERFORMANCE WAS ASSISTED BY THE SWIFT our group and are particularly important ACTION TAKEN BY THE EXECUTIVE TEAM TO in the current environment. I would like to express the thanks of the Board to our ACCELERATE THE INTRODUCTION OF A PLANNED talented team of more than 3,800 people RESTRUCTURING AND COST REDUCTION for their dedication and hard work. PROGRAMME. Board In April, we welcomed Hugh Friel to the Our trading within the Group enjoyed mixed Marketing Services UK businesses Board as a non-executive director. Hugh fortunes. Contract Sales & Marketing are now operating out of the division’s is a former Chief Executive of Kerry Services had an outstanding year while headquarters in
Load more

Recommended publications
  • Corporate Social Responsibility Report 2016 Walgreens Boots Alliance Is the First Global Pharmacy-Led, Health and Wellbeing Enterprise
    Corporate Social Responsibility Report 2016 Walgreens Boots Alliance is the first global pharmacy-led, health and wellbeing enterprise. Our purpose is to help people across the world lead healthier and happier lives. Our 2016 Corporate Social Responsibility Report covers the fiscal year that ended 31 August 2016. In this year’s report: Overview Marketplace Introduction ...................................................1 Our CSR goals .............................................2 28 Our vision, purpose and values ................3 Our approach to CSR .................................4 Contributing to the United Nations Sustainable Development Goals .............6 Transparency ........................................... 30 Our impact ...................................................8 Ethical Sourcing ...................................... 30 ........................... About our Company ................................. 10 External Stakeholders 31 Stakeholder engagement ....................... 12 Workplace Community 32 14 Employee Health and Wellbeing ........ 34 Equal Opportunities .............................. 36 Health and Wellbeing ............................. 16 Health and Safety ...................................37 Young People ........................................... 17 ...................................... Cancer Programs .....................................20 About this report 38 Data management process ................ 38 Environment Data ............................................................ 38 Community data
    [Show full text]
  • OSB Participant List by Research Area
    OSB Participant List by Research Area Contact Centers (CC) • AARP • Air Products and • American Drug Stores Chemicals • AAA • ABB • American Electric Power • Airbus • Accor • Abbott • American Express • Alcatel Lucent • American Electric Power • Abengoa • American International • Alcoa Group • American International • Abu Dhabi National Group Energy Company • Alcon • American Stores Company • Austin Energy • ACC Limited • Alfa • American Water • Bank of America • Access Insurance Holdings • Algonquin Power & • Amgen Utilities • Blue Cross Blue Shield • Accord Holdings • AMIL • ALH Group • Charles Schwab & • ACE • AmInvestment Bank Company • Alitalia • Acea • AMR • Citigroup • ALK Abello • Acer • Amssi • Citizens Gas • Alkermes • Acxiom • Amtran Logistics • Clarke American • Allergan • Adelaide Clinic Holdings • Andrew Corporation • CPS Energy • Alliance & Leicester • Adidas • Anglian Water Services • Direct Energy • Alliance Boots • Advance Food Company • Anritsu • Federal Reserve Bank of • Alliant Techsystems Minneapolis • Advance Publications • Anschutz • Allianz • John Deere • Advanced Coating • Apache • Allied Irish Banks • Technologies Louisville Water Company • Apex Equity Holdings • Advanced Semiconductor • Allstate Insurance • Manila Electric Company Engineering Company • Apple • • • Mellon Financial Adventist Health System Ally Financial • Arcadia Housing • • • MetLife Aegon Alon USA Energy • Arcos Dorados Holdings • • • Morgan Stanley AEON AlpTransit Gotthard • Ardent Health Services • • • NetBank Aera Energy Alstom • Argos •
    [Show full text]
  • Local Businesses – Large and Small
    Local Businesses – Large and Small The details of the local businesses documented below have been researched by the Local History Group. Thomas Glover & Son Thomas Glover & Son, elastic web and fabric manufacturers appeared in the Post Office Directory for Nottinghamshire in 1855. The company is recorded as having several addresses in Nottingham, however it had disappeared from the directory by 1900, returning in 1925 described as a surgical hosier in Chesterfield Street, Carlton. The firm remained at that address until the 1970s. The company’s buildings were on both sides of Chesterfield Street but are now demolished, new houses being built on the side. Turney Brothers In 1861 two brothers, Edward and John Turney built a tannery and began to make leather on a site next to the River Trent and the adjacent canal in Nottingham, known as Sneinton Island. The first buildings took up only a fraction of the space that by the 1920s had developed into a large site with labour-saving machinery imported from many countries. They traded under the name of Turney Brothers and had offices in London, Leicester and Manchester. Edward left some years after the commencement of the company and the driving force was John Turney who was in sole charge for over a quarter of a century. In 1888 the company re-organised into a Limited Company, John being chairman. John led an exceptionally distinguished social, political and commercial life. He was a member of Nottingham Corporation for 46 years, and became Sheriff and then Alderman in 1879 and Mayor for two years 1886 – 1888.
    [Show full text]
  • Corporate Finance Guide 2021 CORPORATE FINANCE GUIDE SPECIAL | CORPORATE
    01/06/2021 15:30 15:30 01/06/2021 01/06/2021 1 1 cover.indd cover.indd Guide Guide Finance Finance Corporate Corporate MIDLANDS BUSINESS INSIDER www.midlandsbusinessinsider.com JULY 2021 JULY midlands businessinsider WEST ™ MIDLANDS insiderEDITION VOL.29 NO.7 £10 JULY 2021 West Midlands Mayor What does business want from Andy Street’s second term? CITY OF CULTURE CITY OFCULTURE Wolverhampton The new home of green construction | SMEGUIDE Mental health | MENTAL HEALTH HEALTH MENTAL Helping a colleague on the edge | RESIDENTIAL AWARDS RESIDENTIALAWARDS | CORPORATE FINANCEGUIDESPECIAL CORPORATE Guide Guide 2021 Corporate Finance Corporate MIDLANDS | CIRCULARECONOMY FIREDHOW A YEAR AS CITY OF CULTURE UP! IS VOL.29 N VOL.29 SPARKING GROWTH IN COVENTRY O 7 MBI July 2021 cover MASTER.indd 1 02/06/2021 15:00 Optimising outcomes for our clients no matter what their destination DLA Piper has been the No 1 M&A law firm, both in the UK and globally, for each of the past 11 years. Trusted adviser to: Put simply, we do things that other law firms cannot. Times 2 SISTERS FOOD GROUP may change, but our qualities do not. Our clients trust us with Advised on the GBP246m sale of part of Fox’s Biscuits to their most important, strategic and transformational M&A and Ferrero Group. ECM transactions. We use our market and sector intelligence and unrivalled deal execution experience to drive and obtain NOBLE GROUP optimal outcomes for our clients, no matter what the deal type, Advised on the sale of chilled dessert brand Gü to Exponent the transaction process, the geography or the counter-party.
    [Show full text]
  • Download Annual Report 2013
    Annual Report 2013 Our goal Our goal is to become Central and Eastern Europe’s leading spirits company – commanding a major stake in each of our core operating markets and making our presence felt in the wider global market. Contents Strategic report Chairman’s statement 02 Group at a glance 04 Our “millionaire” brands 06 Our heritage 08 Chief Executive Officer’s statement 10 Our business model 14 Strategy and KPIs 16 Our markets 18 HIGHLIGHTS Spirits market overview 20 Regional reviews Poland 22 17.4 m €340.5m Czech Republic 24 Italy 26 9 LITRE CASES NET SALES REVENUE Other 27 +11.4% +16.4% Operations 28 2012: 15.6m 9 litre cases 2012: €292.4m Our people 29 Corporate responsibility 30 €83.7m €47.7m Financial review 32 Principal risks 36 ADJUSTED EBITDA* OPERATING PROFIT Directors and +22.3% -44.2% Company Secretary 42 2012: €68.4m 2012: €85.4m Senior management 44 Corporate governance 46 Chairman’s letter 46 €74.4 m €8.9m Corporate governance framework 47 ADJUSTED EBIT* PROFIT FOR THE YEAR Audit Committee report 52 +26.7% -66.0% 2012: €58.7m 2012: €26.2m Nomination Committee report 56 Directors’ remuneration * Stock Spirits Group uses alternative performance measures as key financial indicators to assess the underlying performance of the Group. These include adjusted EBITDA, adjusted EBIT and adjusted free cash flow. report 57 The narrative in the Annual Report & Accounts is based on these alternative measures and an explanation is set out in note 7 to the consolidated financial statements included in the Annual Report & Accounts.
    [Show full text]
  • Glaxosmithkline Aims to Divest Many OTC Brands
    OTC11-02-11p1&28FIN.qxd 8/2/11 11:52 Page 1 11 February 2011 COMPANY NEWS 3 GlaxoSmithKline aims to Valeant expands in CEE 3 with PharmaSwiss deal J&J loses sales of US$1.1bn 4 Boots faces up to tough market 5 divest many OTC brands Key brands boost Novartis OTC sales 6 GSK consumer races ahead 7 laxoSmithKline intends to divest non- to divest the non-core brands as soon as pos- Taisho holds steady in weak market 8 Gcore OTC brands with combined an- sible – hopefully before the end of the year – Vicks shipments lift OTC at P&G 9 nual sales of £500 million (C593 million). depending on buyer interest. Perrigo plans spring Allegra launch 10 Chief executive officer Andrew Witty said The announcement came as GlaxoSmith- Consumer Care grows at Merck & Co 11 the move would enable the company’s Con- Kline reported a 7% rise – 5% at constant ex- Omega reports strong quarter 12 sumer Healthcare division to focus more effec- change rates – in 2010 sales at the Consumer Winter woes hit Boiron 13 tively on its “priority or global” brands as well Healthcare division to £5.01 billion. Sales in Pfizer wants Consumer 14 as its operations in emerging markets. Consumer Healthcare’s OTC Medicines busi- to prove worth A spokesperson for GlaxoSmithKline told ness grew by 5% – 3% at constant exchange OTC bulletin that the company was currently rates – to £2.46 billion. GENERAL NEWS 15 compiling the lists of priority and non-core OTC brands, and hoped to release more details Recent deals with Meda and Valeant Perrigo faces lawsuit over 15 in the second quarter of the year.
    [Show full text]
  • Management Stakeholders
    Hyperglycaemia in acute coronary syndromes: management Stakeholders 15 Healthcare 2gether NHS Foundation Trust 3M Health Care UK 4Children 5 Boroughs Partnership NHS Foundation Trust A.Menarini Pharma U.K. S.R.L. Abbott Diabetes Care Abbott Diagnostics Division Abbott Diagnostics Division Abbott Laboratories Abbott Vascular Devices Abbott Vascular Devices AbbVie AbbVie Abertawe Bro Morgannwg University NHS Trust Achieving for Children Action Heart Action on Addiction Action on Hearing Loss Action on Smoking & Health Action on Smoking and Health Addaction Addenbrookes Hospital Addiction Today ADFAM Adults Strategy and Commissioning Unit Advisory Committee for Community Dentistry Advisory Council on the Misuse of Drugs Afiya Trust African Health Policy Network Aintree University Hospital NHS Foundation Trust Alcohol and Drug service Alcohol Focus Scotland Alcohol Use Disorders: Clinical Management Guideline Development Group Alcoholics Anonymous Alder Hey Children's NHS Foundation Trust Alere Alere Alere International Alere Ltd Alere Ltd Alkermes Inc All Party Parliamentary Group on Vascular Disease Allergan Ltd UK Alliance Boots plc Allocate Software PLC Alpha Medical American Medical Systems Inc. American Medical Systems Inc. American Medical Systems UK Ltd AMORE health Ltd AMORE health Ltd AMORE Studies Group AMORE Studies Group Aneurin Bevan University Health Board anglia community leisure Anglia University Anglian Community Enterprise Ark Therapeutics Ltd Arrhythmia Alliance Arrowe Park Hospital Assocation of NHS Occupational Physicians
    [Show full text]
  • WALGREENS BOOTS ALLIANCE, INC . (Exact Name of Registrant As Specified in Its Charter) Delaware 47-1758322 (State of Incorporation) (I.R.S
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2016 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From ____________ to ___________ Commission file number 001-36759 WALGREENS BOOTS ALLIANCE, INC . (Exact name of registrant as specified in its charter) Delaware 47-1758322 (State of incorporation) (I.R.S. Employer Identification No.) 108 Wilmot Road, Deerfield, Illinois 60015 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (847) 315-2500 Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which registered Common Stock ($.01 Par Value) The NASDAQ Stock Market LLC 2.875% Notes due 2020 New York Stock Exchange 3.600% Notes due 2025 New York Stock Exchange 2.125% Notes due 2026 New York Stock Exchange Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • The Inversion Experience in the United States
    The Inversion Experience in the United States ITPF/TPC Conference on Corporate Inversions and Tax Policy Paul W. Oosterhuis Skadden, Arps, Slate, Meagher & Flom Washington, D.C. January 23, 2015 Beijing Houston Palo Alto Tokyo Boston London Paris Toronto Brussels Los Angeles São Paulo Washington, D.C. Chicago Moscow Shanghai Wilmington Frankfurt Munich Singapore Hong Kong New York Sydney │1 Skadden, Arps, Slate, Meagher & Flom LLP EVOLUTION OF INVERSION TRANSACTIONS Edit│2 on Slide Master │2 Skadden, Arps, Slate, Meagher & Flom LLP INTRODUCTION • This presentation provides background regarding various “inversion” related transactions, and the evolution of those transactions in response to the changing legal landscape. • The basic concept of an inversion is a transaction in which a U.S. parent becomes a subsidiary of a new foreign parent corporation (“NFP”). − If done alone under NFP this is a “self inversion” (Aon, Ensco, etc.). − If done in connection with a target (typically foreign) under NFP this is a combination migration transaction (Eaton/Cooper, Medtronic/Covidien, etc.). • Inversions offer fours main areas of potential tax benefits: 1) Future foreign expansion under NFP outside of the U.S. tax “net” 2) Tax efficient leverage on the group’s U.S. operations 3) Restructuring of legacy foreign operations owned by the U.S. group 4) Better access to offshore cash for NFP dividends, share buybacks, etc. │3 Skadden, Arps, Slate, Meagher & Flom LLP THE START: MCDEROMOTT TRANSACTION (1980’s) Public Public Public McDermott McDermott McDermott
    [Show full text]
  • An Insight Into Our Life Sciences and Healthcare Sector
    An insight into our Life Sciences and Healthcare Sector 2020 allenovery.com 2 An insight into our Life Sciences and Healthcare Sector | 2020 © Allen & Overy LLP 2020 3 Contents Introducing Allen & Overy 04 Full service, international support for the life sciences and healthcare sector 05 M&A/corporate finance 06 Licensing and collaborations 09 Patent litigation 11 Regulatory 13 Dispute resolution/arbitration 14 Equity and debt financing 15 Restructuring 16 Key contacts 17 allenovery.com 4 An insight into our Life Sciences and Healthcare Sector | 2020 Introducing Allen & Overy GEOGRAPHIC SPLIT BY TOTAL NUMBER OF LAWYERS† 141 Central & Eastern Europe 1,016 UK 929 Western Europe 440 129 Asia Pacific 185 Middle East North, Central & South America 77 Africa GLOBAL PRESENCE NORTH AMERICA EUROPE AFRICA ASIA PACIFIC New York Amsterdam Istanbul Casablanca Bangkok Seoul Washington, D.C. Antwerp London Johannesburg Beijing Shanghai Barcelona Luxembourg Hanoi Singapore CENTRAL & Belfast Madrid MIDDLE EAST Ho Chi Minh City Sydney SOUTH AMERICA Bratislava Milan Abu Dhabi Hong Kong Tokyo São Paulo Brussels Moscow Dubai Jakarta* Yangon Bucharest* Munich Perth * Associated office Budapest Paris ** Cooperation office Düsseldorf Prague † All figures represent the Frankfurt Rome financial year 2016/17 Hamburg Warsaw Source: Regional active headcount October 2018 KEY STATISTICS 5,400 2,300 550 40+ Number of staff Number of lawyers Number of partners Offices around the world © Allen & Overy LLP 2020 5 Full service, international support for the life sciences and healthcare sector Our global Life Sciences and Healthcare sector comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, animal health, consumer health, med tech, and diagnostics sectors.
    [Show full text]
  • 1054 PLG Journal Issue 21 01.04.Indd
    Issue 21 | August 2014 www.plg-uk.com The Future for Generics Business Models Factors for Success in the OTC Market Non-Patent Exclusivities in Major Markets Faster Market Access for Precision & More Personalised Medicines SinkorSwiminEurope:theRoleofBusinessDevelopment 7thEuropeanPharmaLicensingSymposium 23rd&24thSeptember2014Prague,CzechRepublic Following the formaƟon of the new PLG CEE group, the EPLS meeƟng travels to Eastern Europe this year for its 7th event. This two day meeƟng will include presentaƟons, talking tables and plenty of networking opportuniƟes both formal and informal. There will be an online delegate contact system open to all registered delegates, with a dedicated oneͲtoͲone meeƟng area available to all delegates throughout the meeƟng. PresentaƟonswill include: Ͳ Overview of Growth OpportuniƟes in Europe Ͳ Are Emerging Markets Paying Their Way? Ͳ The Role of HTA in Assessing BD OpportuniƟes and Deals Ͳ Building By AcquisiƟon Ͳ New Business Models with Pharma Ͳ DeͲRisking Rare Disease Projects Ͳ Launch Strategies in Europe ‘TalkingTables’ With deals becoming increasingly complex, the interacƟve Talking Tables format will enable a range of hot topics to be debated in small groups. The Įndings from each debate will then be presented to the group followed by a panel discussion based on delegate feedback. Issues to be debated will include: Ͳ TerminaƟon Issues in Agreements Ͳ IP Aspects Including SPCs Ͳ Performance Issues in Agreements Ͳ Current Deal Trends Ͳ Consensus Market ForecasƟng Ͳ CoͲBranding Ͳ Due Diligence and Regulatory Issues VenueͲMarrioƩPrague The hotel is centrally located close to Prague Old Town. For those arriving on Monday evening, the informal networking will begin with a drinks recepƟon held at the hotel from 7pm.
    [Show full text]
  • Representative Participant List by Alpha
    Open Standards Benchmarking® Representative Participant List 0-9 2 SISTERS EUROPE A ADOBE SYSTEMS 3M ADP 3S SOLVAY ADRENALIN ESYSTEMS 50HERTZ TRANSMISSION ADVA OPTICAL NETWORKING 7-ELEVEN ADVANCE FOOD COMPANY A AAA ADVANCE PUBLICATIONS AARP ADVANCED BUSINESS GRAPHICS ABB ADVANCED COATING TECHNOLOGIES ABBOTT ADVANCED MICRO DEVICES ABBOTT PRODUCTS ADVANCED SEMICONDUCTOR ENGINEERING ABENGOA ADVENTIST HEALTH SYSTEM ABERCROMBIE & FITCH ADVERTISING RESOURCES ABERTIS TELECOM AEGON ABU DHABI NATIONAL ENERGY COMPANY AEON AC NIELSEN AERA ENERGY ACC LIMITED AERO INVENTORY ACCESS INSURANCE HOLDINGS AEROLÍNEAS ARGENTINA ACCIONA ENERGÍA AES ELETROPAULO ACCOR AETNA ACCORD HOLDINGS AFFILIATED FOODS ACCUITY AFFILIATES MANAGEMENT COMPANY ACCUTEK PACKAGING EQUIPMENT AFH STORES ACE AFLAC INCORPORATED ACE INA INSURANCE AFRICAN DEVELOPMENT BANK ACEA AFRISAM CEMENT ACER AFTONBLADET HIERTA ACME INDUSTRIES AGCO ACTARIS AGF BRASIL INSURANCE ACTEGA TERRA AGFA HEALTHCARE ACXIOM AGFA-GEVAERT ADAPTEC AGGREGATE INDUSTRIES ADELAIDE CLINIC HOLDINGS AGGREKO INTERNATIONAL ADI AGILENT TECHNOLOGIES ADIDAS AGL TORRENS ISLAND HOLDINGS ADITYA BIRLA NUVO LIMITED AGRICOLA FORNACE ADMIRAL INSURANCE COMPANY AGRICULTURAL BANK OF CHINA © 2017 APQC Generated on 12/4/2017 Open Standards Benchmarking® Representative Participant List A AGRO-ON A ALIGN TECHNOLOGY, INC. AICHI BANK ALIMENTATION COUCHE-TARD AIG SEGUROS ALIMENTOS POLAR AIOI NISSAY DOWA INSURANCE ALITALIA AIR CANADA ALK ABELLO AIR CHINA ALKERMES AIR FRANCE ALLAHABAD BANK AIR LIQUIDE ALLEGHANY CORPORATION AIR PRODUCTS ALLEGIANCE
    [Show full text]